Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 1

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jan 15, 2026; 18(1): 112944
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.112944

Table 2 Response rate and disease control rate of patients with evaluable lesions

HAB: High ascites burden; LAB: Low ascites burden.

Citation: Matsumoto T, Sugimoto S, Omori R, Makiyama C, Nakasya A, Nagai H, Yasui H, Higashi R, Sasamoto A, Satake H. Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites. World J Gastrointest Oncol 2026; 18(1): 112944
URL: https://www.wjgnet.com/1948-5204/full/v18/i1/112944.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i1.112944

Matsumoto T, Sugimoto S, Omori R, Makiyama C, Nakasya A, Nagai H, Yasui H, Higashi R, Sasamoto A, Satake H. Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites. World J Gastrointest Oncol 2026; 18(1): 112944 [PMID: 41607769 DOI: 10.4251/wjgo.v18.i1.112944]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.